- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05928767
Hodnocení klinické škály křehkosti (CFS) jako rizikového faktoru úmrtnosti u dospělých pacientů ve věku ≤ 65 let přijatých k intenzivní péči pro septický šok. (Woodstock)
The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.
In the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short/medium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.
The objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.
This analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.
Přehled studie
Postavení
Podmínky
Detailní popis
Recent studies show the impact of frailty in a middle-aged or even young population of patients admitted to critical care in terms of mortality (13), and the persistent risk of impairment of physical and mental capacities after resuscitation (14). To date, few studies have looked at clinical frailty as a risk factor for mortality in a middle-aged or young population, more specifically those suffering from septic shock, which is already known to be a major factor in morbidity and mortality (15,16), with repercussions on long-term quality of life.
The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.
In the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short/medium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.
The objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.
This analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: MELANIE VERLAY
- Telefonní číslo: 03.21.69.10.28
- E-mail: mverlay@ch-lens.fr
Studijní záloha kontaktů
- Jméno: Guillaume DEGOUY, Dr
- Telefonní číslo: 03.21.69.12.34
- E-mail: gdegouy@ch-lens.fr
Studijní místa
-
-
-
Boulogne-sur-Mer, Francie, 62321
- Nábor
- CH Boulogne sur Mer
-
Vrchní vyšetřovatel:
- Charles DETOLLENAERE, Dr
-
Béthune, Francie, 62408
- Nábor
- Ch Germon Et Gauthier
-
Vrchní vyšetřovatel:
- Ghada SBOUI, Dr
-
Dijon, Francie, 21079
- Nábor
- CHU de Dijon
-
Vrchní vyšetřovatel:
- Jean-Pierre QUENOT, Pr
-
Lens, Francie
- Nábor
- CH de Lens
-
Vrchní vyšetřovatel:
- Guillaume DEGOUY, Doctor
-
Lille, Francie, 59037
- Nábor
- CHU Lille
-
Vrchní vyšetřovatel:
- Alexandre GAUDET, Dr
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
All patients admitted to intensive care will be studied for this study. Patients meeting the inclusion criteria and with no non-inclusion criteria will be included in the study after obtaining the patient's or relative's, if applicable, non-objection.
Popis
Inclusion Criteria:
- Patients aged ≥18 years and ≤ 65 years
- Patient admitted to intensive care - resuscitation
- Patient admitted for suspected or documented type 3 sepsis
- Presence of vasopressor amines to maintain MAP > 65mmHg despite filling
- Lactatemia ≥ 2 mmol/L on admission.
Exclusion Criteria:
- Patient moribund on admission
- Patients with severe pre-existing dementia and/or cognitive decline, suffering from severe neurodegenerative diseases that prevent the patient from living independently at baseline, including mental illness requiring institutionalisation, including acquired or congenital mental retardation, etc.
- Pregnant women or women in labour
- Patients under guardianship or curatorship
- Patients deprived of their liberty
- Patient and/or family unable to speak or understand French.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: OTHER
- Časové perspektivy: PROSPECTIVE
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
To show that the frailty score on admission is a risk factor for mortality at D28, independent of known risk factors, in young patients admitted to intensive care (ICU) for sepsis or septic shock.
Časové okno: 28 days after inclusion
|
The odds ratio of frail patients to non-frail patients for the risk of all-cause death at D28 |
28 days after inclusion
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
To study the association, independently of known risk factors, between the frailty score on admission and mortality at day 90.
Časové okno: 90 days after inclusion
|
Time from admission to death or last news, censored at D90 |
90 days after inclusion
|
|
To study the association, independently of known risk factors, between the frailty score on admission and length of hospital stay
Časové okno: 90 days after inclusion
|
The time between admission to IS and live discharge from hospital, death is considered a concurrent risk, the data are censored at 90 days |
90 days after inclusion
|
|
To study the association, independently of known risk factors, between the frailty score on admission and the number of days with recourse to invasive therapies
Časové okno: 90 days after inclusion
|
Number of days with mechanical ventilation, with amines, with recourse to extra-renal purification (EER) during the IS stay. |
90 days after inclusion
|
|
To study the association, independently of known risk factors, between the frailty score on admission and readmission to critical care or hospitalisation before D90, among patients discharged alive from ICU before D90.
Časové okno: 90 days after inclusion
|
Readmission to critical care or hospitalisation before D90, among patients discharged alive from ICU before D90. |
90 days after inclusion
|
|
To study the association, independently of known risk factors, between the frailty score on admission and describe changes in frailty between ICU admission and D90 in patients alive at D90.
Časové okno: 90 days after inclusion
|
Change in frailty score defined by the CFS (continuous) between admission and D90 (in hospital or at home). |
90 days after inclusion
|
|
To study the association, independently of known risk factors, between the frailty score on admission and describe quality of life at D90 in patients alive at D90.
Časové okno: 90 days after inclusion
|
Quality of life measured by the EQ5D score at D90 (in hospital or at home). |
90 days after inclusion
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2023-02
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .